{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:25:47Z","timestamp":1789691147591,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03121-x","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T12:01:55Z","timestamp":1716638515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review"],"prefix":"10.1007","volume":"316","author":[{"given":"Dorra","family":"Guermazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asghar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Yumeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"10","key":"3121_CR1","first-page":"17","volume":"11","author":"C Vinkel","year":"2018","unstructured":"Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthetic Dermatology 11(10):17\u201323","journal-title":"J Clin Aesthetic Dermatology"},{"issue":"5","key":"3121_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ijwd.2021.10.012","volume":"7","author":"EK Kozera","year":"2021","unstructured":"Kozera EK, Lowes MA, Hsiao JL, Frew JW (2021) Clinical considerations in the management of hidradenitis suppurativa in women[Formula presented]. Int J Women\u2019s Dermatology 7(5):664\u2013671","journal-title":"Int J Women\u2019s Dermatology"},{"issue":"1","key":"3121_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","volume":"77","author":"A Garg","year":"2017","unstructured":"Garg A, Lavian J, Lin G, Strunk A, Alloo A (2017) Incidence of hidradenitis suppurativa in the United States: a sex-and age-adjusted population analysis. J Am Acad Dermatol 77(1):118\u2013122","journal-title":"J Am Acad Dermatol"},{"key":"3121_CR4","doi-asserted-by":"crossref","unstructured":"Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G et al (2017) Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clinical, cosmetic and investigational dermatology. :105\u2009\u2013\u200915","DOI":"10.2147\/CCID.S111019"},{"key":"3121_CR5","doi-asserted-by":"crossref","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K (2020) Hidradenitis suppurativa. Nat Reviews Disease Primers. ;6(1)","DOI":"10.1038\/s41572-020-0149-1"},{"key":"3121_CR6","doi-asserted-by":"crossref","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107 Mokos Z (2022) New and emerging targeted therapies for Hidradenitis Suppurativa. Int J Mol Sci. ;23(7)","DOI":"10.3390\/ijms23073753"},{"issue":"5","key":"3121_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40257-019-00439-5","volume":"20","author":"KS Flood","year":"2019","unstructured":"Flood KS, Porter ML, Kimball AB (2019) Biologic Treatment for Hidradenitis Suppurativa. Am J Clin Dermatol 20(5):625\u2013638","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"3121_CR8","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.4081\/dr.2018.7859","volume":"10","author":"A Kyriakou","year":"2018","unstructured":"Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A (2018) Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data. Dermatol Rep 10(2):7859","journal-title":"Dermatol Rep"},{"issue":"10378","key":"3121_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GB, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG et al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747\u2013761","journal-title":"Lancet"},{"issue":"2","key":"3121_CR10","doi-asserted-by":"publisher","first-page":"s129","DOI":"10.25251\/skin.7.supp.129","volume":"7","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Alavi A, Jemec GB, Gottlieb A, Wei X, Wozniak MB et al (2023) Secukinumab in moderate to severe hidradenitis suppurativa: primary endpoint analysis from the SUNSHINE and SUNRISE phase 3 trials. SKIN J Cutan Med 7(2):s129\u2013s","journal-title":"SKIN J Cutan Med"},{"key":"3121_CR11","unstructured":"Novartis P, Novartis Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) 2021 [updated October 2022. https:\/\/ClinicalTrials.gov\/show\/NCT03713632"},{"key":"3121_CR12","unstructured":"Novartis P, Novartis This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) 2021 [updated January 2023. https:\/\/ClinicalTrials.gov\/show\/NCT03713619"},{"issue":"SUPPL 1","key":"3121_CR13","first-page":"77","volume":"30","author":"E Muscianisi","year":"2021","unstructured":"Muscianisi E, Potocki AC, Keefe D, Thomas N, Kasparek T, Kimball AB et al (2021) COVID-19 and treatment with biologics: Safety insights from the phase 3 studies of secukinumab in patients with moderate-to-severe hidradenitis suppurativa. Exp Dermatol 30(SUPPL 1):77\u201378","journal-title":"Exp Dermatol"},{"key":"3121_CR14","unstructured":"Tufts Medical C Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa 2018 [updated June 2019. https:\/\/ClinicalTrials.gov\/show\/NCT03099980"},{"issue":"6","key":"3121_CR15","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524\u20131526","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3121_CR16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"H Van der Zee","year":"2011","unstructured":"Van der Zee H, de Ruiter L, Van Den Broecke D, Dik W, Laman J, Prens E (2011) Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)\u20101\u03b2 and IL\u201010 in hidradenitis suppurativa skin: a rationale for targeting TNF\u2010\u03b1 and IL\u20101\u03b2. Br J Dermatol 164(6):1292\u20131298","journal-title":"Br J Dermatol"},{"issue":"6","key":"3121_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"L Matusiak","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski JC (2009) Increased serum tumour necrosis factor-in Hidradenitis Suppurativa patients: is there a basis for treatment with Anti-tumour Necrosis Factor-\u03b1 Agent\u2019. Acta dermato-venereologica 89(6):601\u2013603","journal-title":"Acta dermato-venereologica"},{"key":"3121_CR18","unstructured":"Florida Academic Dermatology C Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa 2008 [updated November 2008. https:\/\/ClinicalTrials.gov\/show\/NCT00795574"},{"issue":"2","key":"3121_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 62(2):205\u2013217","journal-title":"J Am Acad Dermatol"},{"key":"3121_CR20","unstructured":"Services Institute of Medical Sciences P Efficacy and Safety of Infliximab Biosimilar in Treatment of Resistant Hidradenitis Suppurativa 2023 [updated December 2022. https:\/\/ClinicalTrials.gov\/show\/NCT05663268"},{"issue":"6","key":"3121_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41395-018-0104-x","volume":"113","author":"S Singh","year":"2018","unstructured":"Singh S, Proudfoot J, Xu R, Sandborn WJ (2018) Obesity and response to Infliximab in patients with inflammatory Bowel diseases: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol 113(6):883\u2013889","journal-title":"Am J Gastroenterol"},{"key":"3121_CR22","unstructured":"Penn State U, Amgen Treatment of Hidradenitis Suppurativa Using Etanercept 2008 [updated November 2017. https:\/\/ClinicalTrials.gov\/show\/NCT00949546"},{"issue":"5","key":"3121_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","volume":"146","author":"DR Adams","year":"2010","unstructured":"Adams DR, Yankura JA, Fogelberg AC, Anderson BE (2010) Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 146(5):501\u2013504","journal-title":"Arch Dermatol"},{"key":"3121_CR24","unstructured":"University of P Etanercept for Treatment of Hidradenitis 2008 [updated January 2011 https:\/\/ClinicalTrials.gov\/show\/NCT00107991"},{"issue":"4","key":"3121_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","volume":"60","author":"RA Lee","year":"2009","unstructured":"Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J et al (2009) A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 60(4):565\u2013573","journal-title":"J Am Acad Dermatol"},{"key":"3121_CR26","unstructured":"University of A Etanercept in Hidradenitis Suppurativa [updated May 2006. https:\/\/ClinicalTrials.gov\/show\/NCT00329823"},{"issue":"3","key":"3121_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","volume":"158","author":"E Giamarellos-Bourboulis","year":"2008","unstructured":"Giamarellos-Bourboulis E, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V et al (2008) An open\u2010label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 158(3):567\u2013572","journal-title":"Br J Dermatol"},{"issue":"6","key":"3121_CR28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1600-0625.2009.00967.x","volume":"19","author":"A Pelekanou","year":"2010","unstructured":"Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A et al (2010) Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open\u2010label phase II prospective trial. Exp Dermatol 19(6):538\u2013540","journal-title":"Exp Dermatol"},{"issue":"4","key":"3121_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","volume":"154","author":"C Cusack","year":"2006","unstructured":"Cusack C, Buckley C (2006) Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 154(4):726\u2013729","journal-title":"Br J Dermatol"},{"issue":"4","key":"3121_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE (2011) Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65(4):790\u2013798","journal-title":"J Am Acad Dermatol"},{"key":"3121_CR31","unstructured":"University Medical Center G, Janssen-Cilag BV A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa 2014 [updated February 2015. https:\/\/ClinicalTrials.gov\/show\/NCT01704534"},{"key":"3121_CR32","unstructured":"Jonkman MF, Horv\u00e1th B (2015) USTEKINUMAB IN HIDRADENITIS SUPPURATIVA: A CLINICAL OPEN LABEL STUDY WITH ANALYSES. HIDRADENITIS SUPPURATIVA. :79"},{"issue":"10","key":"3121_CR33","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/exd.14619","volume":"31","author":"AB Kimball","year":"2022","unstructured":"Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I et al (2022) IL-17A is a pertinent therapeutic target for moderate\u2010to\u2010severe hidradenitis suppurativa: combined results from a pre\u2010clinical and phase II proof\u2010of\u2010concept study. Exp Dermatol 31(10):1522\u20131532","journal-title":"Exp Dermatol"},{"key":"3121_CR34","unstructured":"Rockefeller U Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa 2022 [updated July 27 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04979520"},{"key":"3121_CR35","unstructured":"Rockefeller U, Valeant P, Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab 2020 [updated June 4 2020. https:\/\/ClinicalTrials.gov\/show\/NCT03960268"},{"issue":"6","key":"3121_CR36","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","volume":"147","author":"K Navrazhina","year":"2021","unstructured":"Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG (2021) Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol 147(6):2213\u20132224","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3121_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjd.21060","volume":"187","author":"K Navrazhina","year":"2022","unstructured":"Navrazhina K, Frew JW, Grand D, Williams SC, Hur H, Gonzalez J et al (2022) Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol 187(2):223\u2013233","journal-title":"Br J Dermatol"},{"issue":"2","key":"3121_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjd.21591","volume":"187","author":"CH Scheel","year":"2022","unstructured":"Scheel CH, Abu Rached N, Gambichler T (2022) Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol 187(2):138\u2013139","journal-title":"Br J Dermatol"},{"issue":"7","key":"3121_CR39","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.jid.2020.03.896","volume":"140","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Garcet S, Krueger J (2020) 880 targeted IL-17RA antagonism ameliorates histological and transcriptomic features of hidradenitis suppurativa: a proof of concept study. J Invest Dermatology 140(7):S115","journal-title":"J Invest Dermatology"},{"key":"3121_CR40","unstructured":"SRL UCBB, Pharma UCB A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa 2018 [updated April 2022. https:\/\/ClinicalTrials.gov\/show\/NCT03248531"},{"issue":"11","key":"3121_CR41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GB, Forman S, Sayed C, Schmieder G, Weisman J et al (2021) Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatology 157(11):1279\u20131288","journal-title":"JAMA Dermatology"},{"issue":"SUPPL 1","key":"3121_CR42","first-page":"31","volume":"29","author":"GBE Jemec","year":"2020","unstructured":"Jemec GBE, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S et al (2020) Efficacy and safety of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, for the treatment of moderate-to-severe hidradenitis suppurativa (HS): a 12-week, randomised, double-blind, placebo-controlled, phase 2 study. Exp Dermatol 29(SUPPL 1):31\u201332","journal-title":"Exp Dermatol"},{"key":"3121_CR43","unstructured":"SRL UCBB, Pharma UCB A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2021 [updated November 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04242498"},{"key":"3121_CR44","unstructured":"SRL UCBB, Pharma UCB A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2024 [updated March 2023. https:\/\/ClinicalTrials.gov\/show\/NCT04901195"},{"key":"3121_CR45","unstructured":"SRL UCBB, Pharma UCB A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2022 [updated Februrary 2023. https:\/\/ClinicalTrials.gov\/show\/NCT04242446"},{"key":"3121_CR46","unstructured":"Inc A Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep 2023 [updated February 2023. https:\/\/ClinicalTrials.gov\/show\/NCT05355805"},{"key":"3121_CR47","unstructured":"Novartis P, Novartis Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients 2016 [updated July 2022. https:\/\/ClinicalTrials.gov\/show\/NCT02421172"},{"key":"3121_CR48","unstructured":"Kimball A, Prens E, Bechara F, Weisman J, Kolbinger F, Rozenberg I et al (eds) (2019) Hidradenitis suppurativa responds to a novel anti-il17 antibody (CJM112) in a controlled clinical trial vs. placebo. 24th World Congress of dermatology, Milan"},{"issue":"3","key":"3121_CR49","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/jdv.17779","volume":"36","author":"Z Dajnoki","year":"2022","unstructured":"Dajnoki Z, Somogyi O, Medgyesi B, Jenei A, Szab\u00f3 L, G\u00e1sp\u00e1r K et al (2022) Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 36(3):462\u2013471","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3121_CR50","unstructured":"Barbara Horv\u00e1th PI, Janssen-Cilag L, University Medical Center G Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study 2020 [updated August 2019. https:\/\/ClinicalTrials.gov\/show\/NCT04061395"},{"key":"3121_CR51","doi-asserted-by":"crossref","unstructured":"Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P et al (2023) Guselkumab for Hidradenitis Suppurativa: a phase II, open label, mode of action study. Br J Dermatol. :ljad010","DOI":"10.1093\/bjd\/ljad010"},{"key":"3121_CR52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/exd.14413","volume":"31","author":"K Dudink","year":"2022","unstructured":"Dudink K, Bouwman KS, Mu\u00f1oz E, Sathaliya T, Aarts P, Schappin R et al (2022) Guselkumab for HS: a phase II open label, mode of action study. Exp Dermatol 31:74","journal-title":"Exp Dermatol"},{"key":"3121_CR53","unstructured":"Janssen R, Development LLC A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) 2020 [updated June 2021. https:\/\/ClinicalTrials.gov\/show\/NCT03628924"},{"key":"3121_CR54","unstructured":"AbbVie. A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa 2021 [updated August 2022. https:\/\/ClinicalTrials.gov\/show\/NCT03926169"},{"key":"3121_CR55","doi-asserted-by":"crossref","unstructured":"Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S et al (2023) Efficacy and safety of Risankizumab for the treatment of Hidradenitis Suppurativa: a phase 2, Randomized, Placebo-Controlled Trial. Dermatology Therapy. :1\u201313","DOI":"10.1007\/s13555-023-00913-3"},{"issue":"5","key":"3121_CR56","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/bjd.15458","volume":"177","author":"R Thomi","year":"2017","unstructured":"Thomi R, Yerly D, Yawalkar N, Simon D, Schlapbach C, Hunger R (2017) Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol 177(5):1358\u20131366","journal-title":"Br J Dermatol"},{"key":"3121_CR57","unstructured":"AnaptysBio I A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa 2022 [updated February 2023. https:\/\/ClinicalTrials.gov\/show\/NCT04856930"},{"key":"3121_CR58","unstructured":"Boehringer I A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa 2022 [updated September 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04762277"},{"key":"3121_CR59","unstructured":"Boehringer I A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial 2024 [updated March 2023. https:\/\/ClinicalTrials.gov\/show\/NCT04876391"},{"issue":"14","key":"3121_CR60","first-page":"3720","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood J Am Soc Hematol 117(14):3720\u20133732","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"3121_CR61","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-Haendel","year":"2019","unstructured":"Witte-Haendel E, Wolk K, Tsaousi A, Irmer ML, Moessner R, Shomroni O et al (2019) The IL-1 pathway is hyperactive in Hidradenitis Suppurativa and contributes to skin infiltration and Destruction. J Invest DERMATOLOGY 139(6):1294\u20131305","journal-title":"J Invest DERMATOLOGY"},{"issue":"SUPPL 1","key":"3121_CR62","first-page":"87","volume":"30","author":"D Stergianou","year":"2021","unstructured":"Stergianou D, Tzanetakou V, Bolanou A, Kanni T, Micha S, Rellou S et al (2021) Cytokine profile of pus in patients with hidradenitis suppurativa (HS): how it is associated with treatment response to cytokine inhibitors. Exp Dermatol 30(SUPPL 1):87","journal-title":"Exp Dermatol"},{"issue":"1","key":"3121_CR63","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG et al (2016) Safety and Efficacy of Anakinra in severe Hidradenitis Suppurativa A Randomized Clinical Trial. JAMA DERMATOLOGY 152(1):52\u201359","journal-title":"JAMA DERMATOLOGY"},{"key":"3121_CR64","unstructured":"University of California SF Anakinra as a Treatment for Hydradenitis Suppurativa 2013 [updated August 2014. https:\/\/ClinicalTrials.gov\/show\/NCT01516749"},{"issue":"2","key":"3121_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","volume":"70","author":"KS Leslie","year":"2014","unstructured":"Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70(2):243\u2013251","journal-title":"J Am Acad Dermatol"},{"key":"3121_CR66","unstructured":"Janssen R, Development LLC A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa 2020 [updated May 2021. https:\/\/ClinicalTrials.gov\/show\/NCT04019041"},{"key":"3121_CR67","unstructured":"Janssen R, Development LLC A Study of Bermekimab in Patients With Hidradenitis Suppurativa 2019 [updated March 2022. https:\/\/ClinicalTrials.gov\/show\/NCT03512275"},{"issue":"8","key":"3121_CR68","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","volume":"140","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb A, Natsis NE, Kerdel F, Forman S, Gonzalez E, Jimenez G et al (2020) A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatology 140(8):1538\u20131545 e2","journal-title":"J Invest Dermatology"},{"key":"3121_CR69","unstructured":"AbbVie A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy 2023 [updated March 2023. https:\/\/ClinicalTrials.gov\/show\/NCT05139602"},{"issue":"10","key":"3121_CR70","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jid.2021.08.051","volume":"141","author":"H Liu","year":"2021","unstructured":"Liu H, Burn TC, Jackson J, Howell M, Santos LL, Alavi A et al (2021) 049 Janus Kinase 1 inhibitor INCB054707 modulates Disease-Associated markers and pathways in Hidradenitis Suppurativa. J Invest Dermatology 141(10):S157","journal-title":"J Invest Dermatology"},{"issue":"5","key":"3121_CR71","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H et al (2022) Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol 186(5):803\u2013813","journal-title":"Br J Dermatol"},{"key":"3121_CR72","first-page":"69","volume":"30","author":"A Alavi","year":"2021","unstructured":"Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Howell MD et al (2021) A randomized, placebo-controlled, phase 2 study of the Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa. Exp Dermatol 30:69\u201370","journal-title":"Exp Dermatol"},{"key":"3121_CR73","unstructured":"Incyte C A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa 2019 [updated August 13. https:\/\/ClinicalTrials.gov\/show\/NCT03607487"},{"key":"3121_CR74","unstructured":"Incyte C A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa 2019 [updated April 22. https:\/\/ClinicalTrials.gov\/show\/NCT03569371"},{"key":"3121_CR75","unstructured":"Incyte C A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa 2025 [updated March 11. https:\/\/ClinicalTrials.gov\/show\/NCT05620823"},{"key":"3121_CR76","unstructured":"University of Colorado D, National Institute of A, Musculoskeletal, Skin D. Tofacitinib for Immune Skin Conditions in Down Syndrome 2024 [updated January 2023. https:\/\/ClinicalTrials.gov\/show\/NCT04246372"},{"issue":"8","key":"3121_CR77","doi-asserted-by":"publisher","first-page":"B16","DOI":"10.1016\/j.jid.2022.05.962","volume":"142","author":"CA Dunnick","year":"2022","unstructured":"Dunnick CA, Rachubinski A, Enriquez-Estrada B, Worek K, Galbraith M, Smith K et al (2022) LB943 tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome. J Invest Dermatology 142(8):B16","journal-title":"J Invest Dermatology"},{"issue":"2","key":"3121_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","volume":"6","author":"KT Savage","year":"2020","unstructured":"Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB (2020) Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep 6(2):99\u2013102","journal-title":"JAAD Case Rep"},{"key":"3121_CR79","unstructured":"AbbVie A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms 2021 [updated April 22. https:\/\/ClinicalTrials.gov\/show\/NCT04430855"},{"key":"3121_CR80","unstructured":"Incyte C Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa 2023 [updated December 2022. https:\/\/ClinicalTrials.gov\/show\/NCT05635838"},{"key":"3121_CR81","unstructured":"Kirby SJ, Incyte C Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment 2024 [updated December 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04414514"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03121-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03121-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03121-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:34:41Z","timestamp":1719401681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03121-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3121"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03121-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"259"}}